spacer
home > ebr > summer 2004 > a discussion of the ethical issues which surround pharmacogenetics
PUBLICATIONS
European Biopharmaceutical Review

A Discussion of the Ethical Issues which Surround Pharmacogenetics

People often respond differently to the same medicine. Few medicines are effective for everyone and all may cause adverse reactions or even, occasionally, death. Pharmacogenetics, the study of genetic variation between individuals that affects response to medicines, has the potential to play an important role in improving safety and efficacy. Not only do adverse reactions to medicines have significant costs, in both human and monetary terms, but considerable resources are wasted on prescribing medicines that have little or no effect for particular patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Sandy Thomas, Director of the Nuffield Council on Bioethics

Dr Sandy Thomas is Director of the Nuffield Council on Bioethics and Senior Fellow, Science Policy and Technology Research Unit (SPRU) at the University of Sussex. She trained as a Scientist at the University of London (BSc Botany and Zoology, MSc Crop Protection, PhD (Plant Genetics). After lecturing in genetics at the University of London, she became Research Fellow at the Science Policy Research and Technology Unit at the University of Sussex (1987-1997) where she specialised in policy research in life sciences and biotechnology. In 1997, she was appointed as Director of the Nuffield Council on Bioethics through a secondment from the University of Sussex. Over the past decade, she has published widely on the development of public policy for biotechnology, particularly in the area of intellectual property rights and the development and application of genomics. She was a member of the recent UK DFID Commission on Intellectual Property Rights.

spacer
Dr Sandy Thomas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement